MX2015004119A - Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides. - Google Patents
Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides.Info
- Publication number
- MX2015004119A MX2015004119A MX2015004119A MX2015004119A MX2015004119A MX 2015004119 A MX2015004119 A MX 2015004119A MX 2015004119 A MX2015004119 A MX 2015004119A MX 2015004119 A MX2015004119 A MX 2015004119A MX 2015004119 A MX2015004119 A MX 2015004119A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- binding agents
- amyloid binding
- amyloid
- bacteriophage
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 241001515965 unidentified phage Species 0.000 title 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Wood Science & Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se relaciona con agentes y composiciones farmacéuticas para reducir la formación de amiloide y/o para promover la desagregación de proteínas amiloide. Las composiciones también se pueden usar para detectar amiloide.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261708709P | 2012-10-02 | 2012-10-02 | |
| US201261730316P | 2012-11-27 | 2012-11-27 | |
| US201361801349P | 2013-03-15 | 2013-03-15 | |
| US201361828105P | 2013-05-28 | 2013-05-28 | |
| PCT/US2013/062862 WO2014055515A1 (en) | 2012-10-02 | 2013-10-01 | Use of p3 of bacteriophage fusion proteins as amyloid binding agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015004119A true MX2015004119A (es) | 2015-10-26 |
| MX358755B MX358755B (es) | 2018-09-03 |
Family
ID=49354958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015004119A MX358755B (es) | 2012-10-02 | 2013-10-01 | Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9688728B2 (es) |
| EP (1) | EP2906235B1 (es) |
| JP (1) | JP6283366B2 (es) |
| KR (1) | KR102101258B1 (es) |
| CN (1) | CN104870008B (es) |
| AR (1) | AR092879A1 (es) |
| AU (1) | AU2013327472B2 (es) |
| BR (1) | BR112015007424A2 (es) |
| CY (1) | CY1120132T1 (es) |
| DK (1) | DK2906235T3 (es) |
| EA (1) | EA033666B1 (es) |
| ES (1) | ES2641373T3 (es) |
| HR (1) | HRP20171413T1 (es) |
| HU (1) | HUE036893T2 (es) |
| IL (1) | IL238021B (es) |
| LT (1) | LT2906235T (es) |
| MX (1) | MX358755B (es) |
| NZ (1) | NZ706838A (es) |
| PL (1) | PL2906235T3 (es) |
| PT (1) | PT2906235T (es) |
| SI (1) | SI2906235T1 (es) |
| SM (1) | SMT201700473T1 (es) |
| TW (1) | TWI613212B (es) |
| WO (1) | WO2014055515A1 (es) |
| ZA (1) | ZA201502940B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201709849TA (en) | 2011-11-29 | 2017-12-28 | Proclara Biosciences Inc | Use of p3 of bacteriophage as amyloid binding agents |
| LT2906235T (lt) | 2012-10-02 | 2017-10-25 | Proclara Biosciences, Inc. | Bakteriofago sulietų baltymų p3, kaip amiloido rišamųjų agentų, naudojimas |
| US9988444B2 (en) | 2013-05-28 | 2018-06-05 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드 |
| TW202523853A (zh) * | 2015-03-27 | 2025-06-16 | 美商再生元醫藥公司 | 偵測生物污染物之組成物及方法 |
| EP3532497B1 (en) | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| ES2960493T3 (es) | 2018-06-15 | 2024-03-05 | Amyl Therapeutics | Motivo de interacción amiloide general (GAIM) |
| CN115605483A (zh) | 2020-07-06 | 2023-01-13 | 莫尔根生物有限公司（Kr） | 三环双内酯化合物、其生产方法及用途 |
| US20250325558A1 (en) * | 2022-05-25 | 2025-10-23 | Alan Jerome Fowler | Modulation of bace1 as a therapy for spinocerebellar ataxia |
| CN115820567B (zh) * | 2022-07-26 | 2025-06-06 | 成都盛世君联生物技术有限公司 | 耐高温辅助噬菌体tr-3及其应用 |
| WO2024119183A1 (en) | 2022-12-02 | 2024-06-06 | Alzheon, Inc. | Methods for treating neurodegenerative disorders with tramiprosate |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| CA2131003A1 (en) | 1992-05-26 | 1993-12-09 | Raymond G. Goodwin | Novel cytokine that binds cd30 |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US6376117B1 (en) | 2000-07-18 | 2002-04-23 | Sofco L.P. | Internal fuel staging for improved fuel cell performance |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| RU2363707C2 (ru) | 2001-02-19 | 2009-08-10 | Мерк Патент Гмбх | Искусственные белки с пониженной иммуногенностью |
| MXPA03008032A (es) | 2001-03-08 | 2003-12-04 | Merck Patent Gmbh | Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida. |
| AU2002328742A1 (en) * | 2001-10-05 | 2003-04-22 | Cangene Corporation | Phagemid display system |
| DE10238846A1 (de) * | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
| CN101166536B (zh) | 2005-02-01 | 2012-06-27 | 雷蒙特亚特特拉维夫大学有限公司 | 治疗与淀粉样蛋白沉积有关的炎症和涉及已活化小胶质细胞的脑部炎症的方法 |
| AU2007214399A1 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel-Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
| US20090304726A1 (en) | 2006-02-15 | 2009-12-10 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
| WO2007114139A1 (ja) | 2006-04-06 | 2007-10-11 | Fumiaki Uchiyama | 新規繊維状ファージによるファージディスプレイ |
| EP2054515B1 (en) | 2006-07-21 | 2012-01-11 | Ramot at Tel-Aviv University Ltd. | Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates |
| US20100017370A1 (en) | 2006-10-11 | 2010-01-21 | Antitope Limited | T cell epitope databases |
| WO2009143470A1 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
| AU2009316326A1 (en) | 2008-11-24 | 2010-05-27 | Ramot At Tel-Aviv University Ltd. | Method for treating Parkinson' s disease using filamentous bacteriophage |
| EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| EP2683391B1 (en) | 2011-03-11 | 2015-05-06 | Ramot at Tel Aviv University, Ltd. | Filamentous bacteriophage for use in the treatment of neurodegenerative tauopathy |
| SG10201709849TA (en) | 2011-11-29 | 2017-12-28 | Proclara Biosciences Inc | Use of p3 of bacteriophage as amyloid binding agents |
| LT2906235T (lt) | 2012-10-02 | 2017-10-25 | Proclara Biosciences, Inc. | Bakteriofago sulietų baltymų p3, kaip amiloido rišamųjų agentų, naudojimas |
| US9988444B2 (en) | 2013-05-28 | 2018-06-05 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| KR20170085132A (ko) | 2014-12-03 | 2017-07-21 | 프로클라라 바이오사이언시즈, 인크. | 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드 |
-
2013
- 2013-10-01 LT LTEP13776674.7T patent/LT2906235T/lt unknown
- 2013-10-01 TW TW102135558A patent/TWI613212B/zh not_active IP Right Cessation
- 2013-10-01 HU HUE13776674A patent/HUE036893T2/hu unknown
- 2013-10-01 MX MX2015004119A patent/MX358755B/es active IP Right Grant
- 2013-10-01 PL PL13776674T patent/PL2906235T3/pl unknown
- 2013-10-01 DK DK13776674.7T patent/DK2906235T3/en active
- 2013-10-01 PT PT137766747T patent/PT2906235T/pt unknown
- 2013-10-01 HR HRP20171413TT patent/HRP20171413T1/hr unknown
- 2013-10-01 WO PCT/US2013/062862 patent/WO2014055515A1/en not_active Ceased
- 2013-10-01 NZ NZ706838A patent/NZ706838A/en not_active IP Right Cessation
- 2013-10-01 AU AU2013327472A patent/AU2013327472B2/en active Active
- 2013-10-01 EP EP13776674.7A patent/EP2906235B1/en active Active
- 2013-10-01 SM SM20170473T patent/SMT201700473T1/it unknown
- 2013-10-01 US US14/432,861 patent/US9688728B2/en active Active
- 2013-10-01 KR KR1020157011456A patent/KR102101258B1/ko active Active
- 2013-10-01 EA EA201590690A patent/EA033666B1/ru unknown
- 2013-10-01 JP JP2015534813A patent/JP6283366B2/ja active Active
- 2013-10-01 BR BR112015007424-3A patent/BR112015007424A2/pt not_active Application Discontinuation
- 2013-10-01 SI SI201330758T patent/SI2906235T1/sl unknown
- 2013-10-01 CN CN201380061794.6A patent/CN104870008B/zh not_active Expired - Fee Related
- 2013-10-01 ES ES13776674.7T patent/ES2641373T3/es active Active
- 2013-10-02 AR ARP130103572A patent/AR092879A1/es unknown
-
2015
- 2015-03-30 IL IL238021A patent/IL238021B/en active IP Right Grant
- 2015-04-29 ZA ZA2015/02940A patent/ZA201502940B/en unknown
-
2017
- 2017-05-04 US US15/587,180 patent/US10208090B2/en active Active
- 2017-09-20 CY CY20171100988T patent/CY1120132T1/el unknown
-
2018
- 2018-05-09 US US15/975,328 patent/US10526377B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ706838A (en) | Use of p3 of bacteriophage fusion proteins as amyloid binding agents | |
| MX362175B (es) | Composiciones de proteina del gen 3 de bacteriofago y sus usos como agentes de union amiloides. | |
| IN2014DN10386A (es) | ||
| EP2970508A4 (en) | GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE | |
| PT2968418T (pt) | Preparações derivadas de materiais placentários e produção e utilização das mesmas | |
| SMT202000058T1 (it) | Preparazioni liofilizzate di melfalan flufenammide | |
| EP3010494A4 (en) | Compositions and methods using capsids resistant to hydrolases | |
| PH12013500616A1 (en) | Antibody compositions and methods of use | |
| MX2015000754A (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
| IN2015DN00645A (es) | ||
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| PH12015500569A1 (en) | Treated silicas and metal silicates for improved cleaning in dentrifice | |
| UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
| WO2012158493A3 (en) | Compounds that bind to the erythropoietin receptor | |
| IN2015DN02513A (es) | ||
| WO2014052717A3 (en) | Cd20-and egfr-binding proteins enhanced stability | |
| MY168958A (en) | Intermediates and processes for preparing compounds | |
| GB201207064D0 (en) | Pharmaceutical compositions comprising 15-hetre and methods of using the same | |
| ZA201503635B (en) | Lyophilized preparations of melphalan flufenamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: KONINKLIJKE DOUWE EGBERTS B.V. |
|
| FG | Grant or registration |